Project Grant F31CA295016

This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $713,235 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct a randomized controlled trial evaluating the efficacy of the MIND diet in improving cognitive function among breast cancer survivors experiencing cancer-related cognitive impairment. The 5-year project will enroll 200 breast cancer survivors and assess the impact of the...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $166,000 to the University of Southern California to examine how implicit attitudes towards physical activity can mediate the effects of different interventions on physical activity behavior among adults at elevated cancer risk due to inactivity and overweight/obesity. The key products or services being delivered under this grant include: 1) Assessing implicit attitudes...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $402,401 to the University of Missouri System to conduct a pilot study on the feasibility and impact of a metacognitive strategy training (MCST) intervention for women with cancer-related cognitive impairment (CRCI) following breast cancer treatment. The study aims to examine the effects of MCST on cognitive performance, frontoparietal neural functioning, and functional...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $577,778 to Virginia Commonwealth University to investigate the feasibility and acceptability of the FEARLESS protocol, a novel psychological intervention targeting fear of cancer recurrence (FCR) in patients with primary malignant brain tumors and their caregivers. The study aims to address key information gaps related to recruitment methods, study population suitability,...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $133,566 to Virginia Commonwealth University to examine the mechanisms by which physical activity can preserve exercise capacity in women with breast cancer. The project aims to test if increased physical activity during the first 3 months of breast cancer treatment is associated with preserved muscle quality and/or mitigated inflammation, which are contributors...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a $414,446 study at Colorado State University to evaluate the efficacy of a group-based videoconference intervention to increase moderate-to-vigorous physical activity (MVPA) in cancer survivors. The 12-week intervention will include twice-weekly instructor-led group exercise sessions and behavior change discussions, delivered virtually via videoconferencing. The...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $709,050 to the University of North Carolina at Chapel Hill to conduct a randomized controlled trial of the FORTITUDE 2.0 eHealth intervention. The goal is to evaluate the efficacy of this targeted intervention to reduce fear of recurrence among breast cancer survivors, including improving psychological and behavioral outcomes as well as reducing allostatic load (a...

This Project Grant award of $671,757 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund a randomized controlled trial at Virginia Commonwealth University (VCU) to evaluate the impact of a tailored exercise intervention on preserving exercise capacity, left ventricular function, and health-related quality of life in women receiving anthracycline-based chemotherapy for breast cancer. The 5-year study, titled "Supportive Tailored...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $293,053 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to refine and pilot test a supportive psychosocial intervention for patients with malignant primary central nervous system (CNS) tumors. The intervention, which incorporates elements of Acceptance and Commitment Therapy, aims to alleviate distress and promote adaptive...

This Project Grant award of $700,049 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund a study on the impact of targeted tyrosine kinase inhibitor (TKI) therapies on cancer-related cognitive impairment (CRCI) among patients with chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). The study, led by the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, will recruit 200 patients about to begin TKI treatment for CML or CLL,...